REG - Faron Pharma. Oy - Exercise of options

Faron Pharmaceuticals OyAnnouncement

12/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL3269Ca&default-theme=true

RNS Number : 3269C  Faron Pharmaceuticals Oy  12 June 2023

 

Faron Pharmaceuticals Oy

 

("Faron" or "the Company")

 

Exercise of options

Issue of equity

 

Company announcement, June 12, 2023

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, announces that it has received notifications
from option holders to exercise 2015D options over 57,000 shares in the
Company at an exercise price of EUR 1.09 per share and 2015B options over
5,172 shares in the Company at an exercise price of EUR 2.90 per share under
the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and
conditions of the 2015 Option Plan are available on the Company's website at
https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf
(https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf)
.

 

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to
admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth
Market, respectively. Admission of the New Ordinary Shares is expected to
occur on or around June 14, 2023 following issue and registration of the new
Ordinary Shares on or around June 13, 2023 ("Registration"). The New Ordinary
Shares will rank pari passu with existing ordinary shares.

 

Faron's enlarged issued number of shares immediately following Registration
will be 63,559,863 ordinary shares with voting rights attached. The Company
has no shares in treasury; therefore upon, and subject to, Registration, the
total number of voting rights in Faron will be 63,559,863. This figure may be
used by shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in, or a change
to their interest in, the issued shares and votes of the Company.

 

For more information please contact:

 

Investor contacts:

US, Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com (mailto:julia.balanova@faron.com)

Phone: +1 (917) 306-6096

 

EUR, Faron Pharmaceuticals

Yrjö Wichmann

VP, Investor Relations

yrjo.wichmann@faron.com (mailto:yrjo.wichmann@faron.com)

Phone: +358 (0)40 5868 979

 

Media Contact

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), together with its
subsidiaries, is a clinical stage biopharmaceutical group focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its
investigational immunotherapy with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy for patients
with hematological cancers in combination with other standard treatments
including immune checkpoint molecules, and as a monotherapy for untreatable
solid tumors. Faron is headquartered in Turku, Finland. Further information is
available at www.faron.com (http://www.faron.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFFLLFXQLFBBZ